When you're trying to manage your weight, what's a good goal to aim for? A new analysis looked at whether hitting specific targets—like a waist-to-height ratio under 0.53 or a BMI under 27—might be linked to feeling better. The data came from people with obesity in the SURMOUNT-5 trial who were taking either tirzepatide or semaglutide. The analysis found that between 23% and 34% of people on tirzepatide reached at least one of these thresholds, compared to 14% to 21% of those on semaglutide. More importantly, people who got their waist-to-height ratio under 0.53 had more than double the odds of also reaching a state of low disease activity or remission. However, hitting the BMI target wasn't linked to improvements in a physical health quality-of-life score. It's crucial to remember this was a 'post hoc' analysis—meaning researchers looked back at the data after the main trial was done, rather than planning to test these specific targets from the start. This makes the findings more of an interesting observation than a firm conclusion. The results don't prove that reaching these targets causes better health; they only show an association. The idea is that having clear, measurable targets could help doctors and patients have better conversations about treatment goals.
Could hitting specific weight targets help people feel better?
Photo by Cyril Muhammad / Unsplash
What this means for you:
Hitting a specific waist size target was linked to better health, but this is an early observation, not proof. More on Obesity
Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults New Weight Loss Drugs Protect Your Heart and Lower Death Risk
medRxiv · Apr 24, 2026
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes. New Obesity Drug Shows Stronger Weight Loss Than Popular Option
Frontiers · Apr 22, 2026
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study Tirzepatide Saves Money and Health Over Semaglutide
· Apr 22, 2026
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
· May 1, 2026